| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 231 | 2024 | 2341 | 22.060 |
Why?
|
| Carcinoma, Transitional Cell | 94 | 2023 | 962 | 11.150 |
Why?
|
| Cystectomy | 90 | 2024 | 623 | 8.060 |
Why?
|
| Cystoscopy | 12 | 2021 | 88 | 3.120 |
Why?
|
| Neoplasm Invasiveness | 70 | 2024 | 3981 | 3.110 |
Why?
|
| Carcinoma in Situ | 22 | 2023 | 487 | 3.060 |
Why?
|
| BCG Vaccine | 22 | 2023 | 399 | 2.930 |
Why?
|
| Mitomycin | 6 | 2022 | 208 | 2.480 |
Why?
|
| Lymph Node Excision | 30 | 2020 | 1959 | 2.260 |
Why?
|
| Urologic Neoplasms | 9 | 2023 | 188 | 1.990 |
Why?
|
| Neoplasm Recurrence, Local | 60 | 2023 | 10035 | 1.970 |
Why?
|
| Urothelium | 16 | 2021 | 254 | 1.740 |
Why?
|
| Biomarkers, Tumor | 41 | 2023 | 10331 | 1.530 |
Why?
|
| Neoadjuvant Therapy | 21 | 2024 | 4975 | 1.520 |
Why?
|
| Ureteral Neoplasms | 8 | 2022 | 228 | 1.490 |
Why?
|
| Tomography, Optical Coherence | 5 | 2021 | 501 | 1.490 |
Why?
|
| Adjuvants, Immunologic | 13 | 2023 | 657 | 1.300 |
Why?
|
| Carcinoma | 8 | 2021 | 2578 | 1.250 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2021 | 726 | 1.250 |
Why?
|
| Humans | 302 | 2024 | 261506 | 1.240 |
Why?
|
| Cisplatin | 17 | 2024 | 2432 | 1.230 |
Why?
|
| Urinary Bladder | 17 | 2023 | 575 | 1.220 |
Why?
|
| Nomograms | 7 | 2015 | 313 | 1.130 |
Why?
|
| Hydrogels | 3 | 2021 | 123 | 1.120 |
Why?
|
| Kidney Neoplasms | 14 | 2020 | 3022 | 1.070 |
Why?
|
| Neoplasm Staging | 66 | 2021 | 13658 | 1.020 |
Why?
|
| Lymph Nodes | 14 | 2020 | 2967 | 0.960 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 5 | 2022 | 62 | 0.930 |
Why?
|
| Male | 168 | 2022 | 123000 | 0.870 |
Why?
|
| Prostatic Neoplasms | 19 | 2022 | 5767 | 0.870 |
Why?
|
| Lymphatic Metastasis | 33 | 2020 | 4844 | 0.870 |
Why?
|
| Cadherins | 7 | 2005 | 660 | 0.840 |
Why?
|
| Disease Progression | 33 | 2020 | 6682 | 0.840 |
Why?
|
| Administration, Intravesical | 16 | 2023 | 162 | 0.830 |
Why?
|
| Genetic Therapy | 8 | 2020 | 1616 | 0.820 |
Why?
|
| Aged | 126 | 2023 | 70117 | 0.800 |
Why?
|
| Antineoplastic Agents | 30 | 2021 | 14289 | 0.770 |
Why?
|
| Gels | 1 | 2021 | 105 | 0.770 |
Why?
|
| Urinary Diversion | 5 | 2017 | 69 | 0.770 |
Why?
|
| Prognosis | 61 | 2019 | 21713 | 0.760 |
Why?
|
| Prostate | 6 | 2019 | 1088 | 0.750 |
Why?
|
| Female | 156 | 2021 | 141928 | 0.750 |
Why?
|
| Aged, 80 and over | 71 | 2021 | 29902 | 0.740 |
Why?
|
| Robotics | 2 | 2023 | 359 | 0.740 |
Why?
|
| Urinary Tract | 1 | 2021 | 82 | 0.740 |
Why?
|
| Muscles | 6 | 2024 | 416 | 0.740 |
Why?
|
| Middle Aged | 128 | 2021 | 86204 | 0.720 |
Why?
|
| Treatment Outcome | 67 | 2023 | 32848 | 0.720 |
Why?
|
| Robotic Surgical Procedures | 3 | 2023 | 481 | 0.710 |
Why?
|
| Neoplasm Grading | 13 | 2021 | 1742 | 0.700 |
Why?
|
| Clinical Trials as Topic | 15 | 2023 | 3719 | 0.690 |
Why?
|
| Injections, Intradermal | 1 | 2018 | 58 | 0.670 |
Why?
|
| Drug Carriers | 1 | 2020 | 327 | 0.660 |
Why?
|
| Genetic Vectors | 8 | 2020 | 1694 | 0.630 |
Why?
|
| Deoxycytidine | 6 | 2024 | 1353 | 0.620 |
Why?
|
| Transcriptome | 6 | 2019 | 1859 | 0.600 |
Why?
|
| Muscle Neoplasms | 4 | 2015 | 109 | 0.600 |
Why?
|
| Pelvic Neoplasms | 2 | 2015 | 189 | 0.580 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 669 | 0.570 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2016 | 22 | 0.570 |
Why?
|
| Genomics | 7 | 2020 | 2738 | 0.560 |
Why?
|
| Predictive Value of Tests | 19 | 2021 | 4892 | 0.550 |
Why?
|
| Urethral Neoplasms | 2 | 2013 | 60 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2022 | 15862 | 0.530 |
Why?
|
| Vinblastine | 3 | 2015 | 453 | 0.520 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 663 | 0.520 |
Why?
|
| Chemotherapy, Adjuvant | 19 | 2023 | 3890 | 0.510 |
Why?
|
| Splenomegaly | 2 | 2005 | 158 | 0.510 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 2003 | 136 | 0.500 |
Why?
|
| Urinary Reservoirs, Continent | 5 | 2014 | 31 | 0.500 |
Why?
|
| Methotrexate | 4 | 2015 | 999 | 0.490 |
Why?
|
| Occupational Exposure | 2 | 2023 | 244 | 0.480 |
Why?
|
| Thymidine Kinase | 7 | 2003 | 193 | 0.470 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 24 | 2016 | 2390 | 0.470 |
Why?
|
| Follow-Up Studies | 33 | 2018 | 14889 | 0.460 |
Why?
|
| Survival Rate | 31 | 2019 | 12221 | 0.460 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 202 | 0.450 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2014 | 551 | 0.440 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 215 | 0.430 |
Why?
|
| Societies, Medical | 4 | 2020 | 1335 | 0.430 |
Why?
|
| Pelvis | 5 | 2017 | 362 | 0.430 |
Why?
|
| Immunotherapy | 6 | 2023 | 3341 | 0.430 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2018 | 3552 | 0.430 |
Why?
|
| Risk Factors | 34 | 2023 | 17523 | 0.430 |
Why?
|
| Adenoviruses, Human | 3 | 2012 | 181 | 0.420 |
Why?
|
| Surgical Stomas | 1 | 2011 | 20 | 0.420 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1022 | 0.410 |
Why?
|
| Cyclins | 2 | 2004 | 456 | 0.410 |
Why?
|
| Adenoviridae | 5 | 2020 | 1459 | 0.410 |
Why?
|
| Prospective Studies | 17 | 2023 | 12873 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2022 | 2594 | 0.410 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2014 | 200 | 0.400 |
Why?
|
| Prostatectomy | 6 | 2019 | 962 | 0.400 |
Why?
|
| Patient Selection | 5 | 2019 | 2055 | 0.400 |
Why?
|
| Vidarabine | 15 | 2002 | 1341 | 0.390 |
Why?
|
| Endoscopy | 1 | 2014 | 479 | 0.390 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.380 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2001 | 229 | 0.380 |
Why?
|
| Doxorubicin | 5 | 2015 | 3005 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2016 | 447 | 0.370 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 585 | 0.370 |
Why?
|
| Adult | 79 | 2020 | 77950 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2016 | 2330 | 0.360 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 3869 | 0.360 |
Why?
|
| Kidney | 3 | 2022 | 2146 | 0.350 |
Why?
|
| Occupational Diseases | 2 | 2008 | 130 | 0.350 |
Why?
|
| Neoplasm Proteins | 5 | 2014 | 3230 | 0.350 |
Why?
|
| Ganciclovir | 4 | 2003 | 174 | 0.350 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.350 |
Why?
|
| Indoles | 3 | 2012 | 1009 | 0.350 |
Why?
|
| Preoperative Care | 5 | 2016 | 1529 | 0.330 |
Why?
|
| Estrogen Receptor alpha | 3 | 2012 | 701 | 0.330 |
Why?
|
| Pyrroles | 2 | 2012 | 576 | 0.320 |
Why?
|
| Chemoprevention | 2 | 2006 | 241 | 0.320 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 8865 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2403 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 8873 | 0.310 |
Why?
|
| Survival Analysis | 28 | 2017 | 9180 | 0.310 |
Why?
|
| Proportional Hazards Models | 14 | 2018 | 4988 | 0.310 |
Why?
|
| Rhabdomyosarcoma | 2 | 2005 | 341 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 3251 | 0.310 |
Why?
|
| Metabolome | 4 | 2019 | 344 | 0.300 |
Why?
|
| Salvage Therapy | 5 | 2016 | 2054 | 0.300 |
Why?
|
| Clinical Medicine | 1 | 2007 | 24 | 0.300 |
Why?
|
| Fluorescence | 3 | 2014 | 195 | 0.300 |
Why?
|
| Biopsy | 9 | 2021 | 3443 | 0.290 |
Why?
|
| Genetic Loci | 3 | 2014 | 481 | 0.290 |
Why?
|
| Disease-Free Survival | 17 | 2016 | 10001 | 0.280 |
Why?
|
| Multivariate Analysis | 13 | 2014 | 4298 | 0.280 |
Why?
|
| Kidney Pelvis | 3 | 2017 | 102 | 0.280 |
Why?
|
| Atlases as Topic | 2 | 2017 | 42 | 0.280 |
Why?
|
| Immunohistochemistry | 15 | 2016 | 7548 | 0.270 |
Why?
|
| Vena Cava, Inferior | 2 | 2014 | 190 | 0.270 |
Why?
|
| Retinoblastoma Protein | 3 | 2010 | 335 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2018 | 1299 | 0.270 |
Why?
|
| Smoking | 8 | 2023 | 2440 | 0.270 |
Why?
|
| Instillation, Drug | 2 | 2022 | 16 | 0.260 |
Why?
|
| Retrospective Studies | 34 | 2024 | 37905 | 0.260 |
Why?
|
| Time Factors | 18 | 2020 | 12926 | 0.260 |
Why?
|
| DNA Damage | 4 | 2018 | 1954 | 0.260 |
Why?
|
| Carcinoma, Papillary | 3 | 2018 | 584 | 0.260 |
Why?
|
| Fatty Acids | 2 | 2019 | 448 | 0.260 |
Why?
|
| Receptors, Cell Surface | 3 | 2003 | 862 | 0.260 |
Why?
|
| Receptors, Virus | 1 | 2005 | 157 | 0.250 |
Why?
|
| Urine | 2 | 2003 | 143 | 0.240 |
Why?
|
| Carbazoles | 2 | 2014 | 87 | 0.240 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2004 | 35 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2004 | 476 | 0.240 |
Why?
|
| Estrogen Receptor beta | 3 | 2012 | 155 | 0.240 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 52 | 0.240 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 6009 | 0.240 |
Why?
|
| Pyrazoles | 2 | 2014 | 1471 | 0.230 |
Why?
|
| Ribose | 1 | 2023 | 32 | 0.230 |
Why?
|
| Sulfonamides | 2 | 2014 | 1823 | 0.230 |
Why?
|
| Integrin beta1 | 1 | 2004 | 126 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2023 | 324 | 0.230 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 321 | 0.220 |
Why?
|
| Diet | 4 | 2018 | 1440 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2014 | 2326 | 0.220 |
Why?
|
| Sensitivity and Specificity | 8 | 2012 | 4971 | 0.220 |
Why?
|
| DNA Methylation | 5 | 2023 | 2669 | 0.220 |
Why?
|
| Metabolomics | 4 | 2019 | 478 | 0.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2004 | 749 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2024 | 1038 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 408 | 0.220 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 14551 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2023 | 5542 | 0.210 |
Why?
|
| Cell Cycle | 3 | 2018 | 2084 | 0.210 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2018 | 61 | 0.200 |
Why?
|
| Aminolevulinic Acid | 2 | 2014 | 19 | 0.200 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 181 | 0.200 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2012 | 47 | 0.200 |
Why?
|
| Muscle, Smooth | 2 | 2018 | 236 | 0.190 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2001 | 48 | 0.190 |
Why?
|
| Neoplasm Metastasis | 9 | 2021 | 5112 | 0.190 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2000 | 41 | 0.190 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2004 | 534 | 0.190 |
Why?
|
| Mutation | 10 | 2019 | 15179 | 0.190 |
Why?
|
| Regression Analysis | 8 | 2008 | 1546 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 224 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2020 | 5178 | 0.190 |
Why?
|
| Israel | 1 | 2020 | 53 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 1415 | 0.190 |
Why?
|
| Drug Compounding | 1 | 2020 | 70 | 0.180 |
Why?
|
| Folic Acid | 2 | 2018 | 349 | 0.180 |
Why?
|
| Urologic Surgical Procedures | 1 | 2020 | 93 | 0.180 |
Why?
|
| Catheters | 1 | 2021 | 126 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 235 | 0.180 |
Why?
|
| Inactivation, Metabolic | 1 | 2019 | 37 | 0.180 |
Why?
|
| Incidence | 9 | 2018 | 5673 | 0.180 |
Why?
|
| Mutation Rate | 2 | 2017 | 223 | 0.180 |
Why?
|
| Urethra | 4 | 2020 | 144 | 0.180 |
Why?
|
| DNA Repair | 3 | 2018 | 1872 | 0.180 |
Why?
|
| Activin Receptors, Type I | 1 | 1999 | 50 | 0.180 |
Why?
|
| Histone Demethylases | 2 | 2017 | 144 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2018 | 1154 | 0.170 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 27 | 0.170 |
Why?
|
| Simplexvirus | 4 | 2003 | 159 | 0.170 |
Why?
|
| Risk Assessment | 8 | 2022 | 6869 | 0.170 |
Why?
|
| Situs Inversus | 1 | 1998 | 27 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 1130 | 0.170 |
Why?
|
| Drug Synergism | 5 | 2014 | 1313 | 0.170 |
Why?
|
| Ureter | 2 | 2019 | 209 | 0.170 |
Why?
|
| Patient Compliance | 2 | 2014 | 667 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 149 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 1443 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 1506 | 0.160 |
Why?
|
| Counseling | 1 | 2001 | 381 | 0.160 |
Why?
|
| United States | 11 | 2021 | 15433 | 0.150 |
Why?
|
| Sodium Chloride | 1 | 2018 | 156 | 0.150 |
Why?
|
| Genome, Human | 2 | 2017 | 1869 | 0.150 |
Why?
|
| Sexism | 1 | 2017 | 51 | 0.150 |
Why?
|
| Cytomegalovirus | 1 | 2000 | 482 | 0.150 |
Why?
|
| CpG Islands | 1 | 2019 | 633 | 0.150 |
Why?
|
| Hematuria | 2 | 2016 | 85 | 0.150 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 716 | 0.150 |
Why?
|
| Standard of Care | 1 | 2019 | 243 | 0.150 |
Why?
|
| Cohort Studies | 13 | 2019 | 9244 | 0.150 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 419 | 0.150 |
Why?
|
| Case-Control Studies | 13 | 2017 | 6100 | 0.150 |
Why?
|
| Databases, Genetic | 2 | 2017 | 745 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2000 | 842 | 0.140 |
Why?
|
| Mutagens | 1 | 2017 | 187 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 528 | 0.140 |
Why?
|
| Apoptosis | 8 | 2014 | 7591 | 0.140 |
Why?
|
| Blood Cell Count | 1 | 2016 | 225 | 0.140 |
Why?
|
| Medical Oncology | 3 | 2017 | 1423 | 0.140 |
Why?
|
| Phospholipids | 1 | 2017 | 177 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 1996 | 78 | 0.140 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2018 | 287 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 854 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 3101 | 0.140 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 1450 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 384 | 0.140 |
Why?
|
| Tobacco Products | 1 | 2017 | 120 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 2265 | 0.140 |
Why?
|
| Neoplasm Transplantation | 3 | 2008 | 1519 | 0.140 |
Why?
|
| Seminal Vesicles | 3 | 2011 | 152 | 0.140 |
Why?
|
| Genomic Instability | 1 | 2019 | 519 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2016 | 204 | 0.140 |
Why?
|
| Organ Sparing Treatments | 2 | 2021 | 277 | 0.140 |
Why?
|
| Multigene Family | 1 | 2017 | 425 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 636 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 202 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2018 | 6150 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 341 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 1879 | 0.130 |
Why?
|
| Animals | 22 | 2015 | 59536 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2017 | 6207 | 0.130 |
Why?
|
| Celecoxib | 2 | 2014 | 200 | 0.130 |
Why?
|
| Gene Expression Profiling | 6 | 2019 | 5159 | 0.130 |
Why?
|
| Phthalimides | 1 | 2014 | 5 | 0.130 |
Why?
|
| Testicular Neoplasms | 2 | 1996 | 529 | 0.130 |
Why?
|
| Mice | 15 | 2014 | 34495 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 4938 | 0.130 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 3 | 2003 | 107 | 0.130 |
Why?
|
| Neutrophils | 2 | 2016 | 835 | 0.130 |
Why?
|
| Mice, Inbred C3H | 3 | 2000 | 385 | 0.130 |
Why?
|
| Cell Proliferation | 7 | 2017 | 7226 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1999 | 607 | 0.120 |
Why?
|
| Europe | 1 | 2016 | 649 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 41 | 0.120 |
Why?
|
| Angiopoietins | 1 | 2014 | 35 | 0.120 |
Why?
|
| Triglycerides | 1 | 2017 | 603 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 3 | 2014 | 483 | 0.120 |
Why?
|
| Risk | 4 | 2014 | 1972 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3343 | 0.120 |
Why?
|
| Photosensitizing Agents | 1 | 2014 | 71 | 0.120 |
Why?
|
| DNA, Neoplasm | 4 | 2023 | 1910 | 0.120 |
Why?
|
| Recombinational DNA Repair | 1 | 2014 | 79 | 0.120 |
Why?
|
| Dasatinib | 2 | 2015 | 862 | 0.120 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 82 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 1995 | 262 | 0.120 |
Why?
|
| Photoacoustic Techniques | 1 | 2014 | 54 | 0.120 |
Why?
|
| Dinoprostone | 1 | 2014 | 208 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 68 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 1547 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 554 | 0.110 |
Why?
|
| Laparoscopy | 2 | 2020 | 1225 | 0.110 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 77 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2017 | 889 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 259 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2014 | 2819 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2017 | 5539 | 0.110 |
Why?
|
| Prodrugs | 1 | 2014 | 217 | 0.110 |
Why?
|
| Plagiarism | 1 | 2012 | 9 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2014 | 108 | 0.110 |
Why?
|
| Antigens, Differentiation | 2 | 2005 | 238 | 0.110 |
Why?
|
| Kidney Calculi | 2 | 1991 | 40 | 0.110 |
Why?
|
| Sex Factors | 3 | 2014 | 2139 | 0.110 |
Why?
|
| Disease Management | 2 | 2015 | 1052 | 0.110 |
Why?
|
| Indazoles | 1 | 2014 | 297 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2003 | 153 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 469 | 0.110 |
Why?
|
| Chromatography, Liquid | 3 | 2019 | 342 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2014 | 228 | 0.100 |
Why?
|
| Blotting, Western | 4 | 2009 | 3536 | 0.100 |
Why?
|
| United States Food and Drug Administration | 3 | 2021 | 332 | 0.100 |
Why?
|
| Mice, Nude | 7 | 2014 | 4307 | 0.100 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 1258 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2012 | 87 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2011 | 91 | 0.100 |
Why?
|
| Telomerase | 1 | 2014 | 525 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 408 | 0.100 |
Why?
|
| Medicaid | 1 | 2014 | 279 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2015 | 649 | 0.100 |
Why?
|
| Consensus | 3 | 2020 | 978 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2011 | 181 | 0.100 |
Why?
|
| Thalidomide | 1 | 2014 | 569 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2018 | 2588 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 502 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 479 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 244 | 0.090 |
Why?
|
| Genes, p53 | 3 | 2009 | 1090 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2003 | 630 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 993 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 2864 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 5395 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 748 | 0.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 1085 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 6 | 2005 | 4367 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 622 | 0.090 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 280 | 0.090 |
Why?
|
| Fenretinide | 2 | 2008 | 96 | 0.090 |
Why?
|
| Tamoxifen | 3 | 2012 | 876 | 0.090 |
Why?
|
| Analysis of Variance | 5 | 2012 | 2307 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2016 | 650 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2014 | 712 | 0.080 |
Why?
|
| Signal Transduction | 8 | 2024 | 11965 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 543 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2009 | 355 | 0.080 |
Why?
|
| Indolequinones | 1 | 2008 | 4 | 0.080 |
Why?
|
| Aziridines | 1 | 2008 | 17 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 1165 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 203 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 1350 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2019 | 46 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 338 | 0.080 |
Why?
|
| Contrast Media | 2 | 2018 | 1472 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 660 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2010 | 298 | 0.080 |
Why?
|
| Hernia, Abdominal | 1 | 2008 | 41 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2021 | 2316 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2010 | 1656 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2014 | 3821 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2008 | 7222 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 566 | 0.080 |
Why?
|
| Estradiol | 2 | 2012 | 748 | 0.080 |
Why?
|
| ROC Curve | 2 | 2017 | 1183 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 665 | 0.080 |
Why?
|
| Carbon Radioisotopes | 1 | 2007 | 116 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 478 | 0.070 |
Why?
|
| Morbidity | 1 | 2008 | 397 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2008 | 217 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 666 | 0.070 |
Why?
|
| Liver Transplantation | 2 | 2009 | 1112 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 2231 | 0.070 |
Why?
|
| Probability | 3 | 2012 | 866 | 0.070 |
Why?
|
| Biomarkers | 3 | 2023 | 5047 | 0.070 |
Why?
|
| Actuarial Analysis | 3 | 2001 | 159 | 0.070 |
Why?
|
| Immediate-Early Proteins | 2 | 2012 | 107 | 0.070 |
Why?
|
| Selenomethionine | 1 | 2006 | 41 | 0.070 |
Why?
|
| Urogenital Neoplasms | 1 | 2007 | 108 | 0.070 |
Why?
|
| Cause of Death | 3 | 2005 | 752 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2008 | 209 | 0.070 |
Why?
|
| Global Health | 2 | 2008 | 657 | 0.070 |
Why?
|
| Selenium | 1 | 2006 | 47 | 0.070 |
Why?
|
| Life Tables | 3 | 2001 | 120 | 0.070 |
Why?
|
| Urology | 2 | 2020 | 128 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 145 | 0.070 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2005 | 38 | 0.070 |
Why?
|
| Thiazoles | 1 | 2010 | 726 | 0.070 |
Why?
|
| Computational Biology | 3 | 2017 | 1271 | 0.070 |
Why?
|
| Texas | 5 | 2017 | 6311 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 4549 | 0.070 |
Why?
|
| Drainage | 1 | 2007 | 416 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2006 | 204 | 0.060 |
Why?
|
| Calcium Oxalate | 1 | 2005 | 33 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 392 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 1555 | 0.060 |
Why?
|
| Flow Cytometry | 5 | 2005 | 3033 | 0.060 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2005 | 61 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 651 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 1053 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2005 | 51 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 260 | 0.060 |
Why?
|
| Cyclin D1 | 2 | 2012 | 576 | 0.060 |
Why?
|
| Antiviral Agents | 2 | 2003 | 1230 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2006 | 337 | 0.060 |
Why?
|
| Logistic Models | 4 | 2005 | 3441 | 0.060 |
Why?
|
| Quality of Life | 3 | 2014 | 4532 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2022 | 3518 | 0.060 |
Why?
|
| Carotenoids | 1 | 2004 | 96 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 702 | 0.060 |
Why?
|
| Turkeys | 1 | 2003 | 4 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 524 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2004 | 84 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 2 | 2024 | 1121 | 0.060 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2003 | 30 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2024 | 109 | 0.060 |
Why?
|
| Chemical Industry | 1 | 2003 | 9 | 0.060 |
Why?
|
| 2-Naphthylamine | 1 | 2003 | 6 | 0.060 |
Why?
|
| Centrosome | 1 | 2003 | 95 | 0.060 |
Why?
|
| Fertilization | 1 | 2003 | 56 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 1946 | 0.060 |
Why?
|
| Drug Administration Schedule | 7 | 2012 | 3472 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2003 | 290 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 38 | 0.060 |
Why?
|
| Vehicle Emissions | 1 | 2023 | 29 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 755 | 0.060 |
Why?
|
| Phenotype | 4 | 2017 | 6295 | 0.060 |
Why?
|
| Creatinine | 1 | 2005 | 531 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2003 | 106 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 220 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2005 | 434 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2007 | 769 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 2283 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2004 | 196 | 0.050 |
Why?
|
| Transfection | 2 | 2004 | 2944 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 163 | 0.050 |
Why?
|
| Antigens, CD | 3 | 2005 | 1385 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 17 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 1533 | 0.050 |
Why?
|
| Calcinosis | 1 | 2005 | 423 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 460 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 342 | 0.050 |
Why?
|
| Exons | 1 | 2005 | 1328 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 1998 | 1375 | 0.050 |
Why?
|
| Angiomyolipoma | 1 | 2001 | 31 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2001 | 206 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2004 | 1008 | 0.050 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2001 | 61 | 0.050 |
Why?
|
| Cell Movement | 3 | 2017 | 2466 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4078 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 2074 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2292 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2001 | 246 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 157 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 417 | 0.050 |
Why?
|
| Ploidies | 1 | 2000 | 248 | 0.050 |
Why?
|
| SEER Program | 2 | 2016 | 1000 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2001 | 117 | 0.050 |
Why?
|
| Glucuronic Acid | 1 | 2019 | 15 | 0.050 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 18 | 0.050 |
Why?
|
| Herpesviridae | 1 | 2000 | 42 | 0.050 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 43 | 0.050 |
Why?
|
| Biomedical Technology | 1 | 2020 | 35 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 1399 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Retreatment | 1 | 2021 | 452 | 0.040 |
Why?
|
| Genotype | 4 | 2013 | 4109 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3639 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7702 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2001 | 136 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4757 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 95 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 208 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 450 | 0.040 |
Why?
|
| Nephrectomy | 3 | 2014 | 779 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 430 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 1833 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 254 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2022 | 580 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2000 | 471 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2001 | 840 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 4557 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2001 | 478 | 0.040 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 625 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 285 | 0.040 |
Why?
|
| Retinoids | 1 | 1998 | 164 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 35 | 0.040 |
Why?
|
| Disaccharides | 1 | 2017 | 31 | 0.040 |
Why?
|
| Research Design | 1 | 2005 | 1544 | 0.040 |
Why?
|
| Cholic Acids | 1 | 2017 | 30 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2017 | 50 | 0.040 |
Why?
|
| Nitrogenous Group Transferases | 1 | 2017 | 4 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 1163 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 83 | 0.040 |
Why?
|
| Informed Consent | 1 | 2001 | 419 | 0.040 |
Why?
|
| Diglycerides | 1 | 2017 | 37 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 70 | 0.040 |
Why?
|
| Prevalence | 1 | 2005 | 3260 | 0.040 |
Why?
|
| Phosphatidylethanolamines | 1 | 2017 | 63 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 500 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2017 | 61 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 54 | 0.040 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 7 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1997 | 68 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 2278 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 368 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 1123 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 81 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 400 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 2170 | 0.040 |
Why?
|
| Aristolochic Acids | 1 | 2016 | 1 | 0.040 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 68 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 223 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 960 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 661 | 0.040 |
Why?
|
| Splenectomy | 1 | 1997 | 158 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2016 | 1234 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2018 | 169 | 0.040 |
Why?
|
| DNA Adducts | 1 | 2017 | 210 | 0.040 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 70 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 218 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2017 | 147 | 0.040 |
Why?
|
| Ileum | 1 | 1997 | 165 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2010 | 756 | 0.040 |
Why?
|
| Lewis X Antigen | 1 | 2016 | 46 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 671 | 0.040 |
Why?
|
| Survivors | 2 | 2014 | 1031 | 0.040 |
Why?
|
| Stents | 1 | 2023 | 1096 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 1331 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 1960 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 2232 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1997 | 242 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1248 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 1996 | 145 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 4320 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2001 | 2358 | 0.030 |
Why?
|
| Cytosine | 1 | 1996 | 141 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 1294 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Inflammation | 1 | 2005 | 2522 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 1581 | 0.030 |
Why?
|
| Germinoma | 1 | 1995 | 84 | 0.030 |
Why?
|
| Prednisone | 2 | 1998 | 984 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 249 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1995 | 214 | 0.030 |
Why?
|
| Cerebrosides | 1 | 2014 | 9 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2359 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 2693 | 0.030 |
Why?
|
| Molecular Epidemiology | 2 | 2006 | 246 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 684 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2019 | 411 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 2927 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2016 | 250 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 592 | 0.030 |
Why?
|
| Hematoma | 1 | 1995 | 160 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1995 | 250 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2014 | 126 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 211 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 697 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 4821 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 698 | 0.030 |
Why?
|
| Algorithms | 3 | 2017 | 3890 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1225 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 483 | 0.030 |
Why?
|
| Peer Review | 1 | 2014 | 80 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 558 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 4758 | 0.030 |
Why?
|
| Metestrus | 1 | 1992 | 2 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 2173 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 580 | 0.030 |
Why?
|
| Scientific Misconduct | 1 | 2012 | 21 | 0.030 |
Why?
|
| Age Factors | 3 | 2012 | 5377 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2012 | 51 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 703 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 276 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 244 | 0.030 |
Why?
|
| Asparaginase | 1 | 1993 | 184 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 1994 | 1005 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 598 | 0.030 |
Why?
|
| Fever | 3 | 2001 | 497 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1992 | 241 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 1099 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.030 |
Why?
|
| Lithotripsy | 1 | 1991 | 21 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 184 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 2450 | 0.030 |
Why?
|
| Ovarian Follicle | 1 | 1992 | 152 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 471 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 1991 | 55 | 0.020 |
Why?
|
| Alleles | 2 | 2014 | 2437 | 0.020 |
Why?
|
| Azacitidine | 1 | 2017 | 1149 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 107 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1992 | 330 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Keratins | 1 | 2012 | 330 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 550 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2005 | 5270 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 600 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 541 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 2508 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5687 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1993 | 641 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2992 | 0.020 |
Why?
|
| Proteins | 1 | 1998 | 1963 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 383 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 7551 | 0.020 |
Why?
|
| Prednisolone | 2 | 2001 | 123 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2009 | 35 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 575 | 0.020 |
Why?
|
| Prostatic Diseases | 1 | 1989 | 30 | 0.020 |
Why?
|
| Wound Healing | 1 | 2014 | 815 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2009 | 51 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2010 | 195 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1290 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 615 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1823 | 0.020 |
Why?
|
| Selection Bias | 1 | 2009 | 50 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 163 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 237 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 130 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 161 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 3154 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2001 | 864 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 482 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 850 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 760 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 1382 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 15193 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 3045 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 4804 | 0.020 |
Why?
|
| Cysts | 1 | 1989 | 197 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2008 | 2063 | 0.020 |
Why?
|
| Young Adult | 3 | 2010 | 21445 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 396 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 7789 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 2000 | 191 | 0.020 |
Why?
|
| Loss of Heterozygosity | 2 | 1999 | 602 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 287 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 437 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 1998 | 297 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 1997 | 2638 | 0.020 |
Why?
|
| Rituximab | 2 | 2001 | 1528 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 354 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 209 | 0.020 |
Why?
|
| Cyclin E | 1 | 2008 | 267 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 785 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 806 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 4744 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2008 | 269 | 0.020 |
Why?
|
| Remission Induction | 3 | 1998 | 3569 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2005 | 69 | 0.020 |
Why?
|
| Food Analysis | 1 | 2005 | 28 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 1996 | 1870 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1048 | 0.020 |
Why?
|
| Comet Assay | 1 | 2004 | 59 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2004 | 19 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1082 | 0.020 |
Why?
|
| Genes | 1 | 2006 | 491 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4314 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2002 | 3001 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2007 | 731 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2004 | 101 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 875 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2005 | 229 | 0.020 |
Why?
|
| Infant | 2 | 2000 | 13310 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 495 | 0.020 |
Why?
|
| Lymphoma | 1 | 1993 | 1467 | 0.020 |
Why?
|
| Leukemia | 1 | 1993 | 1635 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 626 | 0.010 |
Why?
|
| Models, Biological | 2 | 2006 | 3254 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2017 | 2947 | 0.010 |
Why?
|
| Image Cytometry | 1 | 2003 | 47 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 698 | 0.010 |
Why?
|
| Insemination, Artificial | 1 | 2003 | 12 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2004 | 242 | 0.010 |
Why?
|
| Breeding | 1 | 2003 | 29 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2010 | 1171 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 1541 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2003 | 82 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2000 | 16273 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 6942 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 169 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 268 | 0.010 |
Why?
|
| Rats | 2 | 2008 | 6086 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 519 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 882 | 0.010 |
Why?
|
| Fruit | 1 | 2005 | 294 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 2314 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Vegetables | 1 | 2005 | 325 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 2049 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 1863 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 8223 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 369 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 33 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2054 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 1022 | 0.010 |
Why?
|
| Chills | 1 | 2001 | 16 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2005 | 657 | 0.010 |
Why?
|
| Adolescent | 3 | 2000 | 31252 | 0.010 |
Why?
|
| Palliative Care | 1 | 1992 | 2037 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2001 | 141 | 0.010 |
Why?
|
| Lymphocytosis | 1 | 2001 | 58 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 3570 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 2001 | 119 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 1688 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2001 | 184 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 2489 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1538 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 486 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1489 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 356 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 355 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 588 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2004 | 808 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2001 | 652 | 0.010 |
Why?
|
| Child | 2 | 2000 | 29154 | 0.010 |
Why?
|
| Hypoxia | 1 | 2001 | 443 | 0.010 |
Why?
|
| Dyspnea | 1 | 2001 | 416 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 3203 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 402 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 1998 | 430 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 1073 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 2001 | 587 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1997 | 158 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 1998 | 362 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 788 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2001 | 551 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 875 | 0.010 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2001 | 713 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 689 | 0.010 |
Why?
|
| Fever of Unknown Origin | 1 | 1995 | 63 | 0.010 |
Why?
|
| Seminoma | 1 | 1995 | 81 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2001 | 1085 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2000 | 1274 | 0.010 |
Why?
|
| Mass Screening | 1 | 2003 | 1509 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1995 | 309 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 170 | 0.010 |
Why?
|
| Neutropenia | 1 | 1997 | 968 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 1021 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 15694 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 2843 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1995 | 509 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1681 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1993 | 1471 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 1259 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 1429 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 2045 | 0.010 |
Why?
|
| Bacteremia | 1 | 1995 | 689 | 0.010 |
Why?
|
| Genital Diseases, Male | 1 | 1989 | 27 | 0.010 |
Why?
|
| Pneumonia | 1 | 1995 | 751 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 500 | 0.010 |
Why?
|
| Mullerian Ducts | 1 | 1989 | 76 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1993 | 589 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 4917 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 6089 | 0.000 |
Why?
|